StockData
Mineralys Therapeutics, Inc. logo

Mineralys Therapeutics, Inc. (MLYS) stock

MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$14.48−0.05 (-0.34%)

Close on Nov 17, 2026Market cap $1.28BP/E –Yield –

Mineralys Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Mineralys Therapeutics's total assets was $667.85M at Jun 30, 2026. For fiscal 2025 it was $661.81M, up 221.4% from the year before.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$661.81M+221.4%
FY2024Dec 31, 2024$205.90M-18.2%
FY2023Dec 31, 2023$251.64M+119.9%
FY2022Dec 31, 2022$114.44M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$667.85M+98.9%
Q1 FY2026Mar 31, 2026$652.86M+83.9%
Q4 FY2025Dec 31, 2025$661.81M+221.4%
Q3 FY2025Sep 30, 2025$599.95M+123.6%
Q2 FY2025Jun 30, 2025$335.72M+5.4%
Q1 FY2025Mar 31, 2025$354.94M+2.2%
Q4 FY2024Dec 31, 2024$205.90M-18.2%
Q3 FY2024Sep 30, 2024$268.25M-3.4%
Q2 FY2024Jun 30, 2024$318.49M+9.4%
Q1 FY2024Mar 31, 2024$347.25M+13.3%
Q4 FY2023Dec 31, 2023$251.64M+119.9%
Q3 FY2023Sep 30, 2023$277.56M–
Q2 FY2023Jun 30, 2023$291.22M–
Q1 FY2023Mar 31, 2023$306.44M–
Q4 FY2022Dec 31, 2022$114.44M–

More Mineralys Therapeutics figures

See a number that looks wrong?